OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Gomella on Sequencing Prostate Cancer Therapies

March 25th 2013

Leonard G. Gomella, MD, from the Thomas Jefferson University Hospital Kimmel Cancer Center, discusses the information currently available on sequencing the recently approved treatments for men with metastatic castration-resistant prostate cancer.

Dr. Dixon on the Discrepancy in the Rate of Mastectomies

March 25th 2013

J. Michael Dixon, MBChB, MD, Professor of Surgery, Consultant Surgeon, University of Edinburgh, Clinical Director of the Edinburgh Breast Unit, Western General Hospital, Edinburgh, Scotland, discusses the discrepancy in the rate of mastectomies.

Dr. Mesa on Long-Term Data From the COMFORT Trials

March 25th 2013

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses the long-term experience from the COMFORT-I and COMFORT-II trials in myelofibrosis.

Dr. Melnick on the Future of Chemotherapy in Lymphomas

March 22nd 2013

Ari M. Melnick, MD, Professor of Medicine, Weill Cornell Medical College, discusses the future of chemotherapy in patients with lymphomas.

Emanuel Petricoin on Genomic Profiling and Targeted Therapy

March 22nd 2013

Emanuel "Chip" Petricoin III, PhD, from George Mason University, discusses the inability of DNA and RNA profiling to predict response to treatment with targeted therapies.

Dr. Petrylak on Sipuleucel-T Delaying First Opioid Use

March 21st 2013

Daniel P. Petrylak, MD, from the Smilow Cancer Center at Yale-New Haven, discusses the relationship between sipuleucel-T and time to first use of an opioid analgesic in patients with metastatic castration-resistant prostate cancer.

Dr. Sledge on the Quantitative Measurement of Mutations

March 21st 2013

George W. Sledge, Jr, MD, Chief, Division of Oncology, Professor of Medicine, Stanford University School of Medicine, discusses measuring mutations in human cancers quantitatively.

Dr. Dreicer on Combination Therapies in Prostate Cancer

March 20th 2013

Robert Dreicer, MD, MS, from the Taussig Cancer Institute at the Cleveland Clinic, describes potential combination therapies currently being considered as treatments for men with prostate cancer.

Dr. Cheson on Novel ADCs in Non-Hodgkin Lymphoma

March 20th 2013

Bruce D. Cheson, MD, from Georgetown Lombardi Comprehensive Cancer Center, discusses the prospect of using antibody drug conjugates in non-Hodgkin lymphomas, including follicular lymphoma.

Dr. Caudle Describes the ACOSOG Z1071 Study

March 20th 2013

Abigail S. Caudle, MD, Assistant Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, describes the ACOSOG Z1071 study in breast cancer.

Dr. Crawford Discusses Active Surveillance in Prostate Cancer

March 19th 2013

E. David Crawford, MD, from the University of Colorado, Anschutz Medical Campus, discusses active surveillance as a treatment approach for men with prostate cancer.

Dr. Borgen on the Decision to Undergo a Mastectomy

March 19th 2013

Patrick Borgen, MD, from the Maimonides Breast Cancer Center, details the factors that go into a patient's decision to undergo a mastectomy.

Dr. Erba on Second-Generation TKIs for Chronic Phase CML

March 18th 2013

Harry Erba, MD, PhD, from the University of Alabama at Birmingham, discusses the use of second-generation tyrosine kinase inhibitors for the treatment of chronic phase chronic myeloid leukemia.

Dr. von Minckwitz on pCR and Outcomes in Breast Cancer

March 15th 2013

Gunter von Minckwitz, MD, PhD, Chairman, German Breast Group, Professor of Gynecology, University of Frankfurt, Germany, discusses pathologic complete response (pCR) and outcomes.

Dr. Berenson on Carfilzomib in Refractory Multiple Myeloma

March 15th 2013

James R. Berenson, MD, Medical and Scientific Director, Institute for Myeloma & Bone Cancer Research, Chief Executive Officer, Oncotherapeutics, discusses the a study of carfilzomib as a replacement for bortezomib for multiple myeloma patients refractory to a bortezomib-containing combination regimen.

Dr. Muss Discusses the Need for Geriatric Assessments

March 14th 2013

Hyman B. Muss, MD, Professor of Medicine, Director of Geriatric Oncology, Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill School of Medicine, on the need for geriatric assessments.

Dr. Pinter-Brown on CTCL Combination Therapies

March 13th 2013

Lauren Pinter-Brown, MD, Clinical Professor, Department of Medicine, Hematology-Oncology, University of California, Los Angeles, discusses combination therapies in cutaneous T-cell lymphoma.

Dr. Ford on Docetaxel in Esophagogastric Cancer

March 12th 2013

Hugo Ford, MD, from the Addenbrooke's Hospital in Cambridge, UK, describes which patients with metastatic esophagogastric cancer derive the greatest benefit from second-line treatment with docetaxel.

Dr. Cooperberg on Prostate Cancer Stage Migration

March 12th 2013

Matthew Cooperberg, MD, MPH, from the University of California, San Francisco, discusses the imminent stage migration that is likely to occur as new therapies become available expressly for metastatic prostate cancer.

Dr. Chagpar on the Need for Repeat Biopsy in Breast Cancer

March 12th 2013

Anees Chagpar, MD, MSc, MA, MPH, Associate Professor of Surgery (Oncology), Director, The Breast Center at Smilow Cancer Hospital at Yale-New Haven, discusses the need for repeat biopsy in patients with breast cancer.